Immunohistochemical localization of transforming growth factor-α and transforming growth factor-β during early human fetal prostate development

被引:10
|
作者
Raghow, S [1 ]
Shapiro, E
Steiner, MS
机构
[1] Univ Tennessee, Urol Res Labs, Memphis, TN 38163 USA
[2] NYU, Sch Med, Dept Urol, New York, NY 10003 USA
来源
JOURNAL OF UROLOGY | 1999年 / 162卷 / 02期
关键词
prostate; growth substances; mesoderm; epithelium; androgens;
D O I
10.1016/S0022-5347(05)68617-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We investigated the role of peptide growth factors and androgens in the developing human prostate. Materials and Methods: We performed immunohistochemical staining of prostate tissue sections from human fetuses 9.5, 11.5, 13, 16.5, 18 and 20 weeks in gestation. Results: The temporal and spatial expression of these growth factors was related to the gestational androgen surge. Before the androgen surge (9.5 to 11.5 weeks) transforming growth factor (TGF)-alpha, TGF-beta 1 and TGF-beta 3 but not TGF-beta 2 were present in the mesenchyme. The epithelium exhibited no detectable staining for any of the growth factors. During the androgen peak (13 to 16.5 weeks) TGF-beta 1 decreased and TGF-beta 2 increased in the mesenchyme, and TGF-alpha, TGF-beta 1 and TGF-beta 3 increased in the epithelium. With declining androgen levels TGF-alpha, TGF-beta 2 and TGF-beta 3 remained unchanged but TGF-beta 1 increased in the mesenchyme with no change in the tested peptide growth factor levels in the epithelium. Conclusions: These data suggest that androgens regulate the differential expression of TGF-alpha and TGF-beta, and support a role for peptide growth factors as the direct mediators of androgen action on the mesenchymal and epithelial interactions responsible for prostate development.
引用
收藏
页码:509 / 513
页数:5
相关论文
共 50 条
  • [41] The role of transforming growth factor-β in carcinogenesis
    Karl Hermann Schlingensiepen
    Birgit Fischer-Blass
    Piotr Jachimczak
    Reimar Schlingensiepen
    Nature Reviews Cancer, 2005, 5 : 995 - 995
  • [42] Transforming growth factor-β and the hallmarks of cancer
    Tian, Maozhen
    Neil, Jason R.
    Schiemann, William P.
    CELLULAR SIGNALLING, 2011, 23 (06) : 951 - 962
  • [43] Transforming growth factor-β in myocardial disease
    Nikolaos G. Frangogiannis
    Nature Reviews Cardiology, 2022, 19 : 435 - 455
  • [44] Transforming growth factor-β messaging: #ContextMatters
    Guttmann-Gruber, C.
    Pinon Hofbauer, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (04) : 592 - 593
  • [45] Transforming growth factor-β in critical illness
    Zamora, R
    Vodovotz, Y
    CRITICAL CARE MEDICINE, 2005, 33 (12) : S478 - S481
  • [46] Transforming growth factor-β, 'bad' or 'good'?
    Minoo, P.
    Ramanathan, R.
    NEONATOLOGY, 2008, 93 (04) : 333 - 334
  • [47] Expression of transforming growth factor-α in hepatoblastoma
    Kiss, A
    Szepesi, A
    Lotz, G
    Nagy, P
    Schaff, Z
    CANCER, 1998, 83 (04) : 690 - 697
  • [48] Transforming growth factor-β in myocardial disease
    Frangogiannis, Nikolaos G.
    NATURE REVIEWS CARDIOLOGY, 2022, 19 (07) : 435 - 455
  • [49] The role of transforming growth factor-β in carcinogenesis
    M. Gleave
    B. P. Monia
    Nature Reviews Cancer, 2005, 5 : 995 - 995
  • [50] The transforming growth factor-β superfamily of receptors
    de Caestecker, M
    CYTOKINE & GROWTH FACTOR REVIEWS, 2004, 15 (01) : 1 - 11